JB
Therapeutic Areas
Opus Genetics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OPGx-LCA5 | Leber Congenital Amaurosis (LCA5) | Phase 1/2 |
| OPGx-NR2E3 | Enhanced S-Cone Syndrome / Retinitis Pigmentosa (NR2E3) | Preclinical |
| OPGx-RHO | Retinitis Pigmentosa (RHO) | Preclinical |
| Drug | Indication | Phase |
|---|---|---|
| OPGx-LCA5 | Leber Congenital Amaurosis (LCA5) | Phase 1/2 |
| OPGx-NR2E3 | Enhanced S-Cone Syndrome / Retinitis Pigmentosa (NR2E3) | Preclinical |
| OPGx-RHO | Retinitis Pigmentosa (RHO) | Preclinical |